Welcome to our dedicated page for Kailera Therapeutics SEC filings (Ticker: KLRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kailera Therapeutics' SEC filings document its public-company formation, capital structure, and governance framework following its initial public offering. The company's Form 8-K records the filing of an amended and restated certificate of incorporation, the registration of KLRA common stock on the Nasdaq Global Select Market, and its status as an emerging growth company.
The filing record identifies authorized common stock, undesignated preferred stock authority, Delaware corporate governance matters, and securities registered under Section 12(b) of the Exchange Act. These disclosures provide the formal regulatory record for Kailera's transition into a Nasdaq-listed clinical-stage biotechnology issuer.
Kailera Therapeutics, Inc. (KLRA) reported that its Chief Technology Officer, Nicholson Nur, received a grant of stock options to acquire 220,000 shares of common stock on September 7, 2026 at an exercise price of $16.23 per share, expiring September 7, 2036.
The options vest as to 25% of the underlying shares on August 31, 2027 and thereafter in 36 substantially equal monthly installments, subject to Nur’s continued service through each vesting date. No Rule 10b5-1 trading plan is reported.
Kailera Therapeutics, Inc. (KLRA) reported that Nicholson Nur, who serves as Chief Technology Officer, has filed an initial statement of beneficial ownership on Form 3. The filing lists no transactions or current holdings and notes an attached Exhibit 24 granting a Power of Attorney.
Canada Pension Plan Investment Board, through its wholly owned subsidiary CPP Investment Board Private Holdings (4) Inc., reports beneficial ownership of 7,304,688 shares of Kailera Therapeutics, Inc. common stock. This represents 5.6% of the company’s common stock based on 129,565,608 shares outstanding as of May 20, 2026.
The reporting entities have shared voting and dispositive power over all 7,304,688 shares and no sole voting or dispositive power. The shares are held directly by CPP Investment Board Private Holdings (4) Inc., with Canada Pension Plan Investment Board deemed to share beneficial ownership through its subsidiary.
RTW Investments, LP and Roderick Wong, M.D. reported beneficial ownership of Kailera Therapeutics, Inc. common stock on a Schedule 13G. The reporting persons disclosed beneficial ownership of 10,776,820 shares of common stock, representing 8.3% of the class, based on 129,565,608 shares outstanding as of May 20, 2026.
RTW Investments, a Delaware limited partnership, is the investment adviser to certain funds that directly hold the shares, and Dr. Wong is its Managing Partner and Chief Investment Officer. Both report shared voting and shared dispositive power over the 10,776,820 shares, with no sole voting or dispositive power. The RTW Funds have the right to receive dividends and proceeds from any sale of these shares. The reporting persons state that the filing should not be construed as an admission of beneficial ownership for purposes of Section 13 of the Securities Exchange Act of 1934.
Kailera Therapeutics, Inc., a clinical-stage obesity-focused biotechnology company, reported a larger loss as it ramped R&D and completed its IPO. For the quarter ended June 30, 2026, net loss was $111.3 million, driven by research and development expenses of $101.1 million and general and administrative expenses of $20.3 million. For the first six months of 2026, net loss totaled $190.2 million.
Following its April 20, 2026 initial public offering, which raised $662.0 million in net proceeds, total assets grew to $1.21 billion with cash, cash equivalents and marketable securities of $1,171.8 million as of June 30, 2026. Management states this liquidity is sufficient to fund operations and capital needs for at least twelve months from issuance of the financial statements and into mid‑2028. Kailera remains pre-revenue and continues to advance four GLP‑1–based obesity programs, including lead candidate ribupatide injection now in global Phase 3 trials, under an exclusive license and collaboration with Hengrui.
Kailera Therapeutics reported second quarter 2026 results alongside extensive pipeline updates in obesity treatments. For the quarter ended June 30, 2026, the company recorded a net loss of $111.3 million, wider than $28.9 million a year earlier, driven by substantially higher research and development and general and administrative expenses as multiple clinical programs advanced.
As of June 30, 2026, Kailera held $1,171.8 million in cash, cash equivalents and marketable securities, which it expects will fund operations into mid‑2028. The pipeline includes a global Phase 3 KaiNETIC program for ribupatide injection in obesity, a fully enrolled U.S. Phase 2b high‑dose ribupatide trial, an active IND for ribupatide oral with global Phase 3 initiation planned in the first half of 2027, ongoing global Phase 2 studies of oral GLP‑1 agonist KAI‑7535, and preparations to start a Phase 1 trial of tri‑agonist KAI‑4729 in 2026.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. reported its beneficial ownership in Kailera Therapeutics, Inc. common stock. It holds 11,511,853 shares of common stock, representing 8.9% of the class, based on 129,537,314 shares outstanding as referenced in Kailera’s IPO prospectus filed April 17, 2026.
Jiangsu Hengrui has sole voting and dispositive power over all 11,511,853 shares and no shared power. The position includes 11,511,852 shares held directly by Jiangsu Hengrui and 1 share held by its wholly owned subsidiary, Hengrui (USA) Ltd.
Kailera Therapeutics, Inc. reported that officer Kathleen Tregoning received a grant of stock options covering 175,000 shares of common stock. The options have an exercise price of $23.30 per share and expire on July 6, 2036.
These options vest as to 25% of the underlying shares on June 29, 2027 and then in 36 substantially equal monthly installments, subject to her continued service. Following this grant, she holds stock options exercisable for 175,000 shares directly.
Kailera Therapeutics, Inc. executive Kathleen Tregoning has filed an initial Form 3, which is a required ownership report for company insiders. The filing lists her as an officer of the company with no stock transactions or holdings reported in this submission.
Kailera Therapeutics, Inc. CEO and President Ronald C. Renaud Jr. exercised stock options to acquire 38,094 shares of common stock at an exercise price of $5.25 per share on June 9, 2026. Following the transaction, he directly holds 38,094 common shares.
The exercised options covered 38,094 underlying shares out of a larger grant, with 817,826 stock options reported as remaining after the transaction and expiring on September 19, 2034. The options began vesting on September 9, 2025 and continue vesting in substantially equal monthly installments, conditioned on his continued service.